Evidence map›Paper›PMID 42774284›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Real-world utility of plasma GFAP and NfL in early-onset AD and FTD.

Pratishtha Chatterjee, Svetlana Ivanic, Adam Southon, Claire McCarthy, Sheila K Patel, Maja Christensen, David Darby, Ashley I Bush, Scott Ayton, Michelle M Mielke and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pratishtha ChatterjeeFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.ORCID https://orcid.org/0000-0003-4877-1958
Svetlana IvanicEastern Health Clinical School Monash University Box Hill Victoria Australia.
Adam SouthonFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.
Claire McCarthyEastern Health Clinical School Monash University Box Hill Victoria Australia.
Sheila K PatelFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.
Maja ChristensenDepartment of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia.
David DarbyDepartment of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia.
Ashley I BushFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.
Scott AytonFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.
Michelle M MielkeDepartment of Epidemiology and Prevention Wake Forest University School of Medicine Winston-Salem North Carolina USA.
Emilio WerdenFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.
Amy BrodtmannFlorey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia.ORCID https://orcid.org/0000-0001-9466-2862

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPlasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are promising blood biomarkers, but their real-world diagnostic utility in early-onset dementia is understudied.

methodsPlasma GFAP, NfL, and phosphorylated tau (p-tau)217 were measured using Simoa in 118 patients with cognitive complaints, clinically classified as non-neurodegenerative conditions (non-ND;

resultsGFAP was elevated in EOAD compared to non-ND, FTD, and other-ND, and distinguished EOAD from non-ND (area under the curve [95% confidence interval (CI)]: 0.924 [0.871-0.977]) but performed poorly for FTD versus non-ND (0.636 [0.496-0.775]). NfL was most elevated in FTD and EOAD, distinguishing both (FTD: 0.869 [0.778-0.961]; EOAD: 0.770 [0.673-0.867]) from non-ND, but less effective for FTD versus EOAD (0.750 [0.597-0.903]). GFAP appeared stable in severe renal impairment, while NfL increased. DISCUSSION: These findings support integrating GFAP and NfL into clinical dementia assessments, with GFAP offering added diagnostic specificity in cases of severe renal impairment; however, validation in larger cohorts is needed.

Indexed as

blood biomarkerscognitive disordersearly‐onset Alzheimer's diseaseearly‐onset dementiafrontotemporal dementiatertiary care setting

Identifiers

PMID42774284
PMCPMC13593584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.